ADCT

ADC Therapeutics S.A. NYSE

Healthcare ·Biotechnology ·CH · adctherapeutics.com

$3.68

Mkt Cap $468.1M

52w Low $1.23 65.4% of range 52w High $4.98

50d MA $4.04 200d MA $3.77

P/E (TTM) -3.4x

EV/EBITDA -5.9x

P/B —

Debt/Equity -2.4x

ROE 76.8%

P/FCF -3.2x

RSI (14) —

ATR (14) —

Beta 1.95

50d MA $4.04

200d MA $3.77

Avg Volume 878.9K

About

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituxim…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
May 4, 2026	TNS	-0.19	-0.21	-10.5%	—	—	—	—	—	—	—	—	—
Mar 10, 2026	TNS	-0.32	-0.04	+87.5%	4.80	-1.2%	+1.7%	-9.4%	-14.0%	-12.1%	-14.4%	-21.7%	—
Nov 10, 2025	TNS	-0.40	-0.30	+25.0%	4.21	-1.0%	-5.7%	-3.8%	-3.8%	-5.9%	-5.7%	-4.8%	—
Aug 12, 2025	TNS	-0.36	-0.50	-38.9%	2.94	+1.4%	+5.1%	+8.5%	+6.5%	+10.2%	+5.8%	+13.3%	—
May 14, 2025	TNS	-0.38	-0.36	+5.3%	1.81	+0.6%	-6.6%	+4.4%	+29.3%	+18.8%	+8.8%	+97.8%	—
Mar 27, 2025	TNS	-0.35	-0.29	+17.1%	1.52	-2.6%	-2.0%	-7.2%	-11.2%	-12.5%	-19.1%	-3.9%	—
Nov 7, 2024	TNS	-0.36	-0.42	-16.7%	2.93	+4.4%	+0.0%	+1.7%	+0.0%	-3.8%	-9.6%	+9.6%	—
Aug 6, 2024	TNS	-0.44	-0.38	+13.6%	2.92	+1.0%	-6.2%	-3.8%	-8.9%	-11.3%	-2.7%	-3.1%	—
May 6, 2024	TNS	-0.56	-0.56	+0.0%	4.45	-1.1%	+8.5%	-0.9%	+2.7%	-3.4%	-5.8%	-20.4%	—
Mar 13, 2024	TNS	-0.47	-1.03	-119.1%	3.90	-1.5%	-4.1%	-3.1%	+13.1%	+19.7%	+21.3%	+12.6%	—
Nov 7, 2023	TNS	-0.61	-0.58	+4.9%	0.73	+1.4%	-17.3%	-35.5%	-35.2%	-31.1%	-24.0%	+47.5%	—
Aug 8, 2023	TNS	-0.44	-0.58	-31.8%	1.60	-2.5%	-6.2%	+0.6%	+3.8%	-1.2%	+0.0%	-31.9%	—
May 9, 2023	AMC	-0.80	-0.74	+7.5%	2.17	+1.8%	+10.6%	+11.1%	+7.8%	+22.1%	+12.4%	+15.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.86	$4.10	+6.2%	+4.9%	+2.1%	+2.8%	+2.6%	-4.1%
Oct 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.26	$4.19	-1.6%	-3.1%	-4.2%	+0.7%	-3.1%	-4.5%
Aug 13	Guggenheim	Maintains	Buy → Buy	—	$2.94	$2.98	+1.4%	+5.1%	+8.5%	+6.5%	+10.2%	+5.8%
Jun 20	RBC Capital	Maintains	Outperform → Outperform	—	$3.03	$3.07	+1.3%	-8.6%	-11.6%	-5.9%	-8.9%	-10.9%
Jun 13	Guggenheim	Maintains	Buy → Buy	—	$3.67	$3.57	-2.7%	-2.5%	-7.9%	-11.2%	-17.4%	-24.5%
May 15	RBC Capital	Maintains	Outperform → Outperform	—	$1.81	$1.82	+0.6%	-6.6%	+4.4%	+29.3%	+18.8%	+8.8%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.49	$1.43	-4.0%	-5.4%	-9.4%	-10.7%	-17.4%	-20.8%
Mar 31	Guggenheim	Maintains	Buy → Buy	—	$1.49	$1.43	-4.0%	-5.4%	-9.4%	-10.7%	-17.4%	-20.8%
Mar 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.75	$1.75	+0.0%	+5.1%	-1.1%	-1.7%	+5.7%	+1.1%
Feb 24	Stephens & Co.	Maintains	Overweight → Overweight	—	$1.63	$1.72	+5.5%	-1.8%	-4.3%	-0.6%	-3.1%	+8.0%
Jan 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.02	$2.05	+1.5%	-4.0%	-1.0%	-5.0%	-6.9%	-14.9%
Dec 12	Guggenheim	Maintains	Buy → Buy	—	$2.22	$2.31	+4.1%	-10.8%	-14.9%	-9.9%	-4.1%	-14.0%
Dec 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.48	$3.37	-3.2%	-36.2%	-43.1%	-45.7%	-42.5%	-38.8%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.74	$2.77	+1.1%	+2.6%	-2.9%	-5.5%	+3.6%	+4.0%
Aug 7	RBC Capital	Maintains	Outperform → Outperform	—	$2.92	$2.95	+1.0%	-6.2%	-3.8%	-8.9%	-11.3%	-2.7%
May 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.45	$4.40	-1.1%	+8.5%	-0.9%	+2.7%	-3.4%	-5.8%
Apr 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.39	$4.39	+0.0%	-0.5%	+1.1%	+13.0%	+8.4%	+7.5%
Mar 14	RBC Capital	Maintains	Outperform → Outperform	—	$3.90	$3.84	-1.5%	-4.1%	-3.1%	+13.1%	+19.7%	+21.3%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.82	$4.81	-0.2%	+3.7%	+3.1%	-6.6%	-7.7%	-7.7%
Feb 26	RBC Capital	Maintains	Outperform → Outperform	—	$4.68	$4.76	+1.7%	+9.8%	+7.1%	+3.8%	+3.2%	+3.8%
Feb 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.29	$5.43	+2.6%	-8.9%	-11.3%	-7.6%	-11.5%	-2.8%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.70	$0.75	+6.6%	+1.0%	+2.9%	+0.9%	+4.7%	+2.8%
Nov 9	TD Cowen	Downgrade	Outperform → Market Perform	—	$0.60	$0.59	-1.5%	-22.0%	-21.7%	-16.7%	-8.2%	-2.5%
Nov 8	RBC Capital	Maintains	Outperform → Outperform	—	$0.73	$0.73	+1.4%	-17.3%	-35.5%	-35.2%	-31.1%	-24.0%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.78	$0.80	+3.2%	+3.2%	-1.0%	-6.0%	-7.2%	+4.3%
Sep 12	RBC Capital	Maintains	Outperform → Outperform	—	$1.04	$1.00	-3.8%	-8.2%	-11.1%	-16.1%	-21.2%	-25.4%
Aug 10	JP Morgan	Upgrade	Underweight → Neutral	—	$1.50	$1.56	+4.0%	+7.3%	+10.7%	+5.3%	+6.7%	-3.3%
Aug 9	RBC Capital	Maintains	Outperform → Outperform	—	$1.60	$1.56	-2.5%	-6.2%	+0.6%	+3.8%	-1.2%	+0.0%
Jul 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.31	$1.32	+0.8%	-1.5%	-3.8%	-5.3%	-2.3%	+13.0%
Jul 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.37	$1.95	-17.7%	-21.9%	-36.3%	-34.6%	-36.3%	-33.8%
Jun 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.29	$2.28	-0.4%	-0.4%	-4.8%	-6.6%	-10.5%	-12.7%
May 10	RBC Capital	Maintains	Outperform → Outperform	—	$2.17	$2.21	+1.8%	+10.6%	+11.1%	+7.8%	+22.1%	+12.4%
Apr 24	BofA Securities	Downgrade	Neutral → Underperform	—	$2.30	$2.08	-9.6%	-14.8%	-14.8%	-14.8%	-15.7%	-15.7%
Feb 13	RBC Capital	Maintains	Outperform → Outperform	—	$4.40	$4.45	+1.1%	-1.8%	+0.9%	+0.7%	-1.8%	-1.1%
Jan 24	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.73	$4.85	+2.5%	-1.1%	+0.2%	-0.2%	+6.8%	+4.0%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.59	$3.47	-3.3%	-3.9%	-3.1%	-1.1%	+1.1%	+20.9%
Nov 14	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.10	$4.11	+0.2%	+1.5%	+7.6%	+5.1%	-2.2%	-4.4%
Nov 9	BofA Securities	Downgrade	Buy → Neutral	—	$4.14	$4.00	-3.4%	-3.1%	-3.4%	-1.0%	+0.5%	+6.5%
Nov 9	RBC Capital	Maintains	Outperform → Outperform	—	$4.14	$4.00	-3.4%	-3.1%	-3.4%	-1.0%	+0.5%	+6.5%
Sep 21	JP Morgan	Maintains	Overweight → Overweight	—	$5.29	$5.13	-3.0%	-4.2%	-4.5%	-7.6%	-11.9%	-8.9%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.25	$5.49	+4.6%	+4.4%	+0.8%	-3.4%	-3.8%	-6.9%
Sep 9	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$6.52	$6.08	-6.7%	-5.4%	-8.0%	-12.6%	-14.0%	-16.6%
Aug 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.42	$8.19	-2.7%	-11.4%	-8.1%	-9.4%	-12.9%	-15.3%
Aug 10	RBC Capital	Maintains	Outperform → Outperform	—	$7.97	$8.13	+2.0%	+1.3%	+1.9%	+29.2%	+16.4%	+13.3%
Jul 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.31	$10.33	+0.2%	-8.7%	-11.6%	-13.3%	-18.4%	-21.4%
May 10	RBC Capital	Maintains	Outperform → Outperform	—	$7.81	$8.01	+2.6%	+1.0%	-11.3%	-10.8%	-5.4%	-8.6%
May 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$7.81	$8.01	+2.6%	+1.0%	-11.3%	-10.8%	-5.4%	-8.6%
Apr 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$13.15	$13.47	+2.4%	+6.5%	+10.4%	+7.9%	+2.4%	+0.5%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.77	$15.00	+1.6%	-4.7%	-5.2%	-5.8%	-0.5%	-3.2%
Feb 1	Morgan Stanley	Maintains	Overweight → Overweight	—	$15.89	$15.88	-0.1%	+4.8%	-0.1%	-0.9%	+1.5%	+3.1%

Recent Filings

8-K · 2.02 !! High

ADC Therapeutics S.A. -- 8-K 2.02: Earnings Results

ADC Therapeutics reported Q1 2026 earnings results, providing investors with updates on operational performance and financial condition for the quarter ended March 31, 2026.

May 4

8-K

Unknown — 8-K Filing

ADCT's strong $261.3M cash position funds operations through 2028, but near-term stock sentiment depends on LOTIS-5 Phase 3 results due mid-2026, making clinical data timing critical for investor confidence.

Mar 10

8-K · 1.01 !! High

ADC Therapeutics SA -- 8-K 1.01: Material Agreement

ADC Therapeutics amended its royalty agreement with HealthCare Royalty Management, which has provided $300 million in cumulative funding, potentially affecting the company's financial obligations and cash flow structure.

Feb 23

Data updated apr 24, 2026 10:54am · Source: massive.com